Abstract:Abstract Abstract 1905 Multiple myeloma (MM) is a fatal plasma cell malignancy mainly localized in the bone marrow. The clonal expansion of tumor cells is associated with the disappearance of normal plasma cells and with a marked depression in the production of normal immunoglobulin (Ig). This makes MM patients highly vulnerable to bacterial, fungal and viral infections and recurrent infections remain to be a major cause of death in MM patients. It has been shown that most primary myeloma cells and cell lines express multiple Toll-like receptors (TLRs). Among them, TLR4 is most frequently expressed. To investigate TLR-initiated responses in MM cells including proliferation, anti-apoptosis and immune escape, we first screened four commonly used human myeloma cell line (HMCL) for the expression of major TLRs by RT-PCR. Surprisingly, all the HMCL expressed multiple TLRs. We also examined primary myeloma cells from 4 patients with MM and our results showed that TLR4 was expressed by all the tumor cells. We incubated myeloma cells with LPS, the natural ligand for TLR4, and found that cell proliferation increased significantly. Targeting TLRs on malignant B cells can induce resistance to chemotherapeutic agents but can also be exploited for combined therapeutic approaches. As mechanisms involved in the resistance to apoptosis play a major role in MM escape to therapies, we sought to determine the capacity of TLR4 ligand to promote the survival of HMCL cells. Myeloma cells were pretreated for four hours with LPS before being induced apoptosis by adriamycin. Results showed that LPS pretreatment partially protected the cells from adriamycin-induced apoptosis. The TLR signaling pathway activates several signaling elements, including NF-kB and ERK/JNK/p38 MAPKs, which regulate many immunologically relevant proteins. Time-dependent MAPK phosphorylation was measured to assess the activation of these kinases upon treatment with LPS in cell lines. ERK1/2, p38, and JNK phosphorylation and NF-kB were significantly up-regulated following LPS treatment. Moreover, our findings demonstrated that LPS-induced cell proliferation was dependent on JNK, ERK and p38 signaling. IL-18, a recently described member of the IL-1 cytokine superfamily, is now recognized as an important regulator of innate and acquired immune responses. In this study, we found that LPS induced IL-18 secretion and activated MAPK and NF-kB signaling simultaneously. Therefore, our results suggest that activation of the MAPK signaling and secretion of IL-18 are interconnected. Tumors evade immune surveillance by multiple mechanisms, including the production of factors such as TGF-β and VEGF, which inhibit and impair tumor-specific T cell immunity. Our study also showed that T cell proliferation induced by allostimulatory cells decreased when the HMCL were pre-treated with LPS. Moreover, immunoregulatory molecules on HMCL, such as B7-H1, B7-H2 and CD40, were upregulated after treatment with LPS, suggesting that TLR4 ligand LPS facilitates tumor cell evasion of the immune system. Our results show that TLRs are functional on myeloma tumor cells, and the ligands to these TLRs have a functional role in affecting myeloma cell proliferation, survival, and response to chemotherapy and immune attacks. Disclosures: No relevant conflicts of interest to declare.

LGR4 promotes tumorigenesis by activating TGF-β1/Smad signaling pathway in multiple myeloma

[Involvement of LMO4 in Tumorigenesis Associated Epithelial-Mesenchymal Transition].

LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway

Activated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth

LGR4 Modulates Breast Cancer Initiation, Metastasis, and Cancer Stem Cells

CAMKIIγ is a Targetable Driver of Multiple Myeloma Through CaMKIIγ/ Stat3 Axis

Gambogenic Acid Exerts Antitumor Activity in Hypoxic Multiple Myeloma Cells by Regulation of Mir-21

Expression and Function of Toll-Like Receptors in Multiple Myeloma Patients: Toll-Like Receptor Ligands Promote Multiple Myeloma Cell Growth and Survival Via Activation of Nuclear Factor-Kappa B

LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma

Triggering Of Toll-Like Receptor-4 In Human Multiple Myeloma Cells Promotes Proliferation And Alters Cell Responses To Immune And Chemotherapy Drug Attack

Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack.

AGBL4 promotes malignant progression of glioblastoma via modulation of MMP-1 and inflammatory pathways

LAMP5 May Promote MM Progression by Activating P38.

Long Noncoding RNA TUG1 Promotes Proliferation and Inhibits Apoptosis in Multiple Myeloma by Inhibiting Mir-29B-3p.

Pgc1 Beta Regulates Multiple Myeloma Tumor Growth Through Ldha-Mediated Glycolytic Metabolism

Overexpression of SMC4 activates TGFβ/Smad signaling and promotes aggressive phenotype in glioma cells

LGR4 Attenuates MGP Expression and Suppresses EGFR Activation-Induced Triple-Negative Breast Cancer Metastasis

TTK Promotes Multiple Myeloma Progression by Regulating RGN Expression

CXCL10 recruitment of γδ T cells into the hypoxic bone marrow environment leads to IL-17 expression and multiple myeloma progression

Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma.

LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway